{"id":9129,"date":"2025-11-03T10:56:53","date_gmt":"2025-11-03T07:56:53","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9129"},"modified":"2025-11-03T10:56:53","modified_gmt":"2025-11-03T07:56:53","slug":"mitral-valve-disease-in-2025-evolving-treatment-pathways-from-esc-guidelines-and-tct-advances","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/mitral-valve-disease-in-2025-evolving-treatment-pathways-from-esc-guidelines-and-tct-advances\/","title":{"rendered":"Mitral Valve Disease in 2025: Evolving Treatment Pathways from ESC Guidelines and TCT Advances"},"content":{"rendered":"
Mitral Valve Disease in 2025: Evolving Treatment Pathways from ESC Guidelines and TCT Advances<\/div>\n
<\/div>\n
Sources: TCT 2025 Conference, October 29 2025-Medscape Medical News | ESC\/EACTS Guidelines for Valvular Heart Disease ,Eur Heart J. 2022<\/div>\n
<\/div>\n
1.\u00a0 Overview<\/div>\n
Mitral valve disease \u2014 either mitral regurgitation (MR) or mitral stenosis (MS) \u2014 remains a leading cause of heart failure and mortality worldwide.<\/div>\n
Recent transcatheter technologies presented at TCT 2025 have expanded treatment possibilities for elderly or high-risk patients once considered inoperable.<\/div>\n
<\/div>\n
2.\u00a0 Treatment Overview<\/div>\n
\u2022 Surgical repair remains the gold standard for mitral valve disease whenever feasible and safe, providing the most durable correction and best long-term survival.<\/span><\/div>\n
\u2022 When surgery is not possible because of high operative risk or complex anatomy, transcatheter options such as TEER (edge-to-edge repair) or TMVR (transcatheter replacement) offer effective, less-invasive alternatives supported by recent ESC guidelines and TCT 2025 findings.<\/span><\/div>\n
<\/div>\n
3.\u00a0 Mitral Regurgitation (MR): Treatment Options<\/div>\n
1. Medical Therapy<\/span><\/div>\n
\u2022 Guideline-directed therapy for heart failure (ACE inhibitors\/ARBs\/ARNIs, beta-blockers, SGLT2 inhibitors, diuretics).<\/span><\/div>\n
2. Surgical Repair or Replacement<\/span><\/div>\n
\u2022 Repair preferred in primary MR when durable.<\/span><\/div>\n
\u2022 Replacement (mechanical or bioprosthetic) when repair is not feasible.<\/span><\/div>\n
3. Transcatheter Edge-to-Edge Repair (TEER)<\/span><\/div>\n
\u2022 Definition: Minimally invasive catheter technique joining the mitral leaflets to reduce regurgitation.<\/span><\/div>\n
\u2022 Devices: MitraClip (Abbott) and Pascal (Edwards).<\/span><\/div>\n
\u2022 Approach: Via femoral vein \u2192 transseptal puncture.<\/span><\/div>\n
\u2022 Indication: Severe primary or secondary MR with high surgical risk or inoperable status.<\/span><\/div>\n
\u2022 Evidence: COAPT and MITRA-FR trials showed reduced HF hospitalizations and mortality.<\/span><\/div>\n
\u2022 Guideline status: Class I\/IIa recommendation in ESC 2021.<\/span><\/div>\n
4. Transcatheter Mitral Valve Replacement (TMVR)<\/span><\/div>\n
\u2022 For patients unsuitable for surgery or TEER due to anatomy or severe calcification (MAC).<\/span><\/div>\n
\u2022 Devices: Tendyne (Abbott) and Sapien M3 (Edwards).<\/span><\/div>\n
\u2022 TCT 2025 trials (SUMMIT-MAC, ENCIRCLE) showed major improvements in survival and symptoms at 1 year.<\/span><\/div>\n
5. Adjunctive Therapies<\/span><\/div>\n
\u2022 Cardiac resynchronization therapy (CRT) for functional MR.<\/span><\/div>\n
\u2022 Atrial fibrillation control and anticoagulation as indicated.<\/span><\/div>\n
<\/div>\n
4.\u00a0 Mitral Stenosis (MS): Treatment Options<\/div>\n
1. Medical Management<\/span><\/div>\n
\u2022 Symptom control with diuretics, rate control (in AF), and anticoagulation to prevent embolism.<\/span><\/div>\n
2. Percutaneous Balloon Mitral Valvotomy (PBMV \/ PTMC)<\/span><\/div>\n
\u2022 First-line for rheumatic MS with pliable leaflets and no significant MR or thrombus.<\/span><\/div>\n
3. Surgical Commissurotomy or Valve Replacement<\/span><\/div>\n
\u2022 For non-pliable or heavily calcified valves, or associated valvular disease.<\/span><\/div>\n
4. Transcatheter Mitral Valve Replacement (TMVR)<\/span><\/div>\n
\u2022 New option for severe calcification (MAC) or prohibitive surgical risk; Tendyne approved (FDA 2025).<\/span><\/div>\n
<\/div>\n
5.\u00a0 Mitral Annular Calcification (MAC)<\/div>\n
\u2022 Chronic calcium deposition stiffens the mitral annulus \u2192 mixed stenosis and regurgitation with heart failure and arrhythmia.<\/span><\/div>\n
\u2022 Common in elderly women with hypertension, diabetes, or renal disease.<\/span><\/div>\n
\u2022 Surgery often impractical; TMVR (Tendyne) now offers a lifesaving alternative.<\/span><\/div>\n
<\/div>\n
6.\u00a0 Key Takeaways<\/div>\n
\u2022 Surgical repair remains the preferred and most durable option when feasible.<\/span><\/div>\n
\u2022 TEER is the main transcatheter solution for high-risk MR.<\/span><\/div>\n
\u2022 TMVR (Tendyne, Sapien M3) is transforming care for inoperable or calcified valves.<\/span><\/div>\n
\u2022 Balloon valvotomy remains first-line for rheumatic MS.<\/span><\/div>\n
\u2022 Heart Valve Team decision-making and advanced imaging are vital for optimal outcomes.<\/span><\/div>\n
\u2022 TCT 2025 results mark a turning point toward effective, less invasive mitral valve therapy for \u201cno-option\u201d patients.<\/span><\/div>\n
<\/div>\n
https:\/\/click.mail.medscape.com\/?qs=d93a08ef9e8080cf9c36a328057decfe7aac679fb1cfef4966e35e8d3d28a860fb3face426ee5394ea357052e0af8948cdf5addf95a864fc0be8434f712b516f<\/a><\/div>\n
<\/div>\n
<\/div>\n
http:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Valvular-Heart-Disease-Guidelines<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Mitral Valve Disease in 2025: Evolving Treatment Pathways from ESC Guidelines and TCT Advances Sources: TCT 2025 Conference, October 29 2025-Medscape Medical News | ESC\/EACTS Guidelines for Valvular Heart Disease ,Eur Heart J. 2022 1.\u00a0 Overview Mitral valve disease \u2014 either mitral regurgitation (MR) or mitral stenosis (MS) \u2014 remains a leading cause of heart […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9129","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9129"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9129\/revisions"}],"predecessor-version":[{"id":9131,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9129\/revisions\/9131"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}